Drug
Allo 316
Allo 316: highest development phase Phase 1, developed by Allogene Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Allogene Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALLO-316 NCT04696731 | Phase 1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma |
Latest
No recent events.
Follow Allo 316 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.